

November 20, 2014



Matinas BioPharma to Present at Two Investor Conferences in Early December

- LD Micro Main Event VII Presentation and Live Audio Webcast on Wednesday, December 3, 2014, at 3:00 p.m. PST / 6:00 p.m. EST -

- RetailInvestorConferences.com Live and Interactive Online Presentation on Thursday, December 4, 2014, at 12:00 p.m. PST / 3:00 p.m. EST -

BEDMINSTER, N.J., Nov. 20, 2014 (GLOBE NEWSWIRE) -- [Matinas BioPharma Holdings, Inc.](#) ("Matinas BioPharma" or the "Company") (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced that Roelof Rongen, President and Chief Executive Officer, will be presenting a corporate overview highlighting the recent clinical progress of Matinas BioPharma's lead product candidate [MAT9001](#) at two upcoming investor conferences during the first week of December of 2014.

Event: [LD Micro Main Event VII](#) micro-cap investor conference
Date: Wednesday, December 3, 2014
Time: 3:00 p.m. Pacific Standard Time / 6:00 p.m. Eastern Standard Time
Location: Luxe Sunset Hotel in Los Angeles, CA

A live audio webcast of the LD Micro presentation will be available on the Company's website (www.matinasbiopharma.com) in the Investor Relations section under Events (<http://ir.matinasbiopharma.com/events>) with a webcast replay available approximately two hours after the presentation for a period of one month.

Event: [RetailInvestorConferences.com](#) virtual investor conference
Date: Thursday, December 4, 2014
Time: 12:00 p.m. Pacific Standard Time / 3:00 p.m. Eastern Standard Time
Location: [RetailInvestorConferences.com](#) website

A live, interactive online webcast of the RetailInvestorConferences.com presentation will be available directly through [RetailInvestorConferences.com](#), a real-time event where investors are invited to ask questions online and may access the presenting company's "virtual trade booth." An on demand archive will be available on [RetailInvestorConferences.com](#) for 90 days. Matinas BioPharma will also post a link to the virtual conference in the Company's Investor Relations section of the corporate website under Events (<http://ir.matinasbiopharma.com/events>).

About LD Micro

LD Micro is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published reports on select companies throughout the year. The firm also hosts the LD Micro Invitational. LD Micro is a non-registered investment advisor. For more information, please contact (408) 457-1042 or visit www.ldmicro.com.

About RetailInvestorConferences.com

Since 2010, RetailInvestorConferences.com, created by BetterInvesting (NAIC), PR Newswire, and MUNCmedia, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform. Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.

About MAT9001

[MAT9001](#) is a proprietary prescription-only omega-3 fatty acid-based composition, comprising docosa-pentaenoic acid (DPA) and other omega-3 fatty acids, which is under development for therapeutic applications with severe hypertriglyceridemia (TG > 500 mg/dL) as the lead indication. Promising pre-clinical studies with DPA and MAT9001 indicate distinctive therapeutic response properties. The Company has recently filed an IND for MAT9001 and initiated its first human study in November 2014. The Company believes that its development program and related clinical investigations may yield an improved therapeutic profile compared to existing therapies, based on MAT9001's differentiating mechanistic features associated with its unique composition.

About Matinas BioPharma

Matinas BioPharma is a development stage biopharmaceutical company, founded in 2011, with a focus on identifying and developing novel pharmaceutical products for the treatment of abnormalities in blood lipids, referred to as dyslipidemia, and the treatment of cardiovascular and metabolic diseases. Led by an experienced management team and a board of directors with a history of building pharmaceutical companies, Matinas is focused on creating the next generation of omega-3-fatty-acid-based pharmaceutical products. Our lead product, MAT9001, which takes advantage of advancements in the field of lipidomics, has been specifically designed and formulated for therapeutic applications in the dyslipidemia field. For more information, please visit www.matinasbiopharma.com and connect with the Company on [Twitter](#), [LinkedIn](#), [Facebook](#), and [Google+](#).

Forward Looking Statements: *This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, cash flow and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could", "believes," "estimates" and*

similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of MAT9001; our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials for MAT9001; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statement to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma's lead product candidate MAT9001 is in a development stage and is not available for sale or use.

CONTACT: Investor and Media Contact
Jenene Thomas
Investor Relations and Corporate Communications Advisor
Jenene Thomas Communications, LLC
Phone: +1 (908) 938-1475
Email: jthomas@matinasbiopharma.com

Source: Matinas BioPharma Holdings, Inc.